


Figure 1




Figure 2




Figure 3




Figure 4A




Figure 4B




Figure 4C



ligand 0uM
MFI
20000
15000
10000
5000
0
Ab log10 conc (nM)
Humanized 506E15.CysMab.DAPA
Humanized 121G12.CysMab.DAPA
Humanized 674J13.CysMab.DAPA
ligand 1uM
MFI
20000
15000
10000
5000
0
Ab log10 conc (nM)
Humanized 506E15.CysMab.DAPA
Humanized 121G12.CysMab.DAPA
Humanized 674J13.CysMab.DAPA

Figure 5



N-term
EC2 loop
EC50 (% of WT)
250
200
150
100
50
0
WT
F44Y
L47V
R201K
S204G
Q206D
M208L
I213V
E215A
Cell line mutations
MAB197
121G12
674J13
908E15

Figure 6




Figure 7A




Figure 7B




Figure 8




Figure 9




Figure 10




Figure 11




Figure 12




Figure 13



No treatment
IgG1.CysMab.DAPA.MPET.DM4 10 mg/kg
121G12.CysMab.DAPA.MPET.DM4 2 mg/kg
121G12.CysMab.DAPA.MPET.DM4 10 mg/kg

Figure 14A



Mean phospho-Histone H3 ratio with StDev
50
40
30
20
10
0
Untreated
IgG1.CysMab.DAPA.MPET.DM4
121G12.CysMab.DAPA.MPET.DM4 2mg/kg
121G12.CysMab.DAPA.MPET.DM4 5mg/kg
121G12.CysMab.DAPA.MPET.DM4 10mg/kg

Figure 14B



Mean Tumor Volume (mm3) ± SEM
1000
500
0
0
5
10
15
20
25
30
Dose D1
Dose D15
Day of Treatment
No Treatment
hIgG1.CysMab.DAPA.MPET.DM4 2 mg/kg
121G12.CysMab.DAPA.MPET.DM4 0.5 mg/kg
121G12.CysMab.DAPA.MPET.DM4 1 mg/kg
121G12.CysMab.DAPA.MPET.DM4 2 mg/kg

Figure 15



Mean Tumor Volume (mm3) ± SEM
2000
1500
1000
500
0
0
5
10
15
20
25
Dose D1
Dose D15
Day of Treatment
No Treatment
hIgG1.CysMab.DAPA.MPET.DM4 5 mg/kg
121G12.CysMab.DAPA.MPET.DM4 2 mg/kg
121G12.CysMab.DAPA.MPET.DM4 5 mg/kg

Figure 16



Mean Tumor Volume (mm3) ± SEM
2500
2000
1500
1000
500
0
0
5
10
15
20
25
30
35
40
Dose D1
Dose D15
Day of Treatment
No treatment
hIgG1.CysMab.DAPA.MPET.DM4 2 mg/kg
121G12.CysMab.DAPA.MPET.DM4 2 mg/kg
n=2 of 4 sac'd D28

Figure 17



Mean Tumor Volume (mm3) ± SEM
2000
1500
1000
500
0
0
5
10
15
20
25
30
35
Dose
D1
Dose
D15
Day of Treatment
No Treatment
121G12.CysMab.DAPA.MPET.DM4 0.5 mg/kg
121G12.CysMab.DAPA.MPET.DM4 2 mg/kg
121G12.CysMab.DAPA.MPET.DM4 5 mg/kg

Figure 18




Figure 19A




Figure 19B



100
10
1
0.1
Concentration (ug/mL)
0
100
200
300
400
500
Time (h)
0.5 mpk (total Ab)
0.5 mpk (ADC)
1 mpk (total Ab)
1 mpk (ADC)
2 mpk (total Ab)
2 mpk (ADC)

Figure 20




Figure 21A




Figure 21B



1000
100
10
1
0.1
0.01
Concentration (ug/mL)
0
100
200
300
400
500
600
700
800
Time (h)
1 mg/kg tAb
3 mg/kg tAb
8 mg/kg tAb
1 mg/kg ADC
3 mg/kg ADC
8 mg/kg ADC

Figure 22



ESCALATION (SA)
EXPANSION* (SA)
R/R CLL and NHL
N ~28
CCR7 ADC Q3W
MTD/RD
R/R CLL n~20
R/R PTCL n~20
R/R DLBCL n~20
R/R MCL n~20
R/R FL n~20

Figure 23